8 in 10 health apps have significant security vulnerabilities

More than 8 in 10 (84 percent) of U.S. FDA-approved health apps tested by IT security vendor Arxan Technologies did not adequately address at least two of the Open Web Application Security Project top 10 risks, according to the firm's 5th Annual State of Application Security Report. 

Most of the mobile health apps were susceptible to application code tampering and reverse-engineering--95 percent of the FDA-approved apps, and 100 percent of the apps formerly approved by the U.K.'s National Health Service, lacked binary protection, which could result in privacy violations, theft of personal health information and tampering.

Arxan discovered a wide disparity between consumer confidence in the level of security incorporated into mobile health apps and the degree to which organizations address known application vulnerabilities. While the majority of app users and app executives said they believe their apps to be secure, nearly all the apps Arxan assessed, including FDA-approved health apps, proved to be vulnerable to at least two of the top 10 serious security risks.

Arxan's research analyzed apps from the U.S., U.K., Germany and Japan.

“Mobile apps are often used by organizations to help keep customers ‘sticky,’ yet in the rush to bring new apps to market, organizations tend to overlook critical security measures that are proving crucial to consumer loyalty,” said Patrick Kehoe, Arxan's CMO. “Our research demonstrates that mobile app security is an important element in customer retention. Baking in robust mobile app security is not only a smart technology investment to keep the bad guys out, but also a smart business investment to help organizations differentiate from the competition and to achieve customer loyalty based on trust.”

Access the complete report.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.